My Application Form Status

Check the status of your application form with Angel Broking.
  • Companies
  • Everything else
Search

Dishman Pharmaceuticals and Chemicals Ltd Research Report - 17th Aug 2016

Pharmaceutical | Published on Aug 17th 2016

IT

The company posted better than expected results for 1QFY2017 with sales at Rs366cr V/s Rs350cr expected and V/s Rs400cr in 1QFY2016, a yoy de-growth of 8.5%. CRAMS (Rs258cr) posted a growth of 2.3% yoy and the Market Molecules other segment (Rs108cr) posted de-growth of 26.9% yoy. On the operating front, the EBITDA margin came in at 25.3% V/s 20.9% expected and V/s 25.4% in 1QFY2016. Thus, the Adj. net profit came in at Rs46cr V/s Rs32cr expected and V/s Rs40cr in 1QFY2016, a yoy growth of 13.7%. We recommend a SELL. Results better than expected on all fronts: Company posted better than expected results for 1QFY2017 with sales at Rs366cr V/s Rs350cr expected and V/s Rs400cr in 1QFY2016, a yoy de-growth of 8.5%. CRAMS (Rs258cr) posted a growth of 2.3% yoy and Market Molecules (Rs108cr) posted de-growth of 26.9% yoy. Within CRAMS, Carbogen Amcis (Rs202.3cr) posted a yoy growth of 14.3%, CRAMS India (Rs42.1cr) posted de-growth of 37.0% and CRAMS UK (Rs13.5cr) posted a yoy growth of 62.4%. Market Molecules declined on back of Vitamin D (Rs62.6cr; a yoy de-growth of 28.4%), while the other segment (Rs45.7cr) posted a yoy de-growth of 24.8%. On the operating front, the EBITDA margin came in at 25.3% V/s 20.9% expected and V/s 25.4% in 1QFY2016. Thus, the Adj. net profit came in at Rs46cr V/s Rs32cr expected and V/s Rs40cr in 1QFY2016, a yoy growth of 13.7% Outlook and valuation: We expect Dishman’s net sales and net profit to grow at a CAGR of 10.0% and 3.1%, respectively, over FY2016-18E. At current levels, Dishman is trading at 15.1x its FY2018E earnings. We believe the current valuations are expensive, given the restrained growth and low profitability; hence, we maintain our SELL rating on the stock.

Download Full Report

Accumulate

CMP 170
Target Price 45
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)3,726.59
MCAP NSE (Rs in Cr)3,734.66
P/E (x)18.91
EPS (Rs.)12.21
BV (Rs.)67.03
Div Yield (%)0.43
FV (Rs.)2.00
P/BV (x)2.25
EV/Sales (x)2.94
EV/EBITDA (x)13.13

Shareholding Pattern (%)

Promoter61.0
Foreign16.0
Public & Others14.0
Institution7.0
Corporate2.0
Grand Total100.0

Trade Securely

AngelEye

Portfolio Tracking & Trading Application View Demo